Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kanebo Ltd.

www.kanebo.co.jp

Latest From Kanebo Ltd.

Contamination and Raw Material Testing Issues Raised in FDA Warning Letters

FDA investigators are continuing to find contamination problems and inadequate testing, according to 20 warning letters issued in the first half of 2013, as well as a troubling trend of repeat observations at Baxter, Hospira and Apotex. Observers say to expect more sterility concerns in future warning letters, particularly involving mold, as FDA ramps up GMP enforcement at compounding pharmacies.

Kanebo Recalls Rhododenol-Based Skin Brighteners From Asian Markets

As many as 450,000 units under an array of brands are being recalled by Kao Corporation’s Kanebo Cosmetics unit following reports suggesting that the company’s Rhododenol brightening ingredient can leave white blotches on skin.

Consumer Asia Pacific

Kanebo Recalls Rhododenol-Based Skin Brighteners From Asian Markets

As many as 450,000 units under an array of brands are being recalled by Kao Corporation’s Kanebo Cosmetics unit following reports suggesting that the company’s Rhododenol brightening ingredient can leave white blotches on skin.

Consumer Asia Pacific

Digene's Long Road Towards a Blockbuster

After spending a decade developing its technology and product development capabilities, centered on testing for human papillomavirus, the cause of cervical cancer, Digene Corp. is growing its top line and finally gaining visibility. Now, the question is whether it can validate its test clinically and secure its market position, which means dislodging an entrenched cytology infrastructure. If successful, the company could become a superstar. On the other hand, its proprietary position could be undermined by other cervical cancer markers that appear downstream of initial HPV infection and have a higher correlation with disease. And Digene's focus on the HPV product opportunity has limited its efforts in developing its core technology at a time when other companies are dedicating significant resources to similar efforts.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Kanebo Ltd.
  • Senior Management
  • Takashi Hoashi, Chmn. & Pres.
  • Contact Info
  • Kanebo Ltd.
    Phone: (81) 3 5446 3006
    17-4, Sumida 5-Chome
    Sumida-Ku
    Tokyo, 131-0031
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register